Premium
The Association of British Neurologists' myasthenia gravis guidelines
Author(s) -
Sussman Jon,
Farrugia Maria E.,
Maddison Paul,
Hill Marguerite,
Leite M. Isabel,
HiltonJones David
Publication year - 2018
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.13503
Subject(s) - myasthenia gravis , expert opinion , medicine , audit , evidence based medicine , association (psychology) , clinical practice , intensive care medicine , neuromuscular disease , evidence based practice , scientific evidence , disease , medline , family medicine , alternative medicine , psychology , psychiatry , psychotherapist , pathology , political science , management , philosophy , epistemology , law , economics
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence‐based medicine. Despite the basic principles of treatment being well known, patients continue to receive suboptimal treatment. A myasthenia gravis guidelines group was therefore established under the aegis of the Association of British Neurologists. These guidelines attempt to steer a path between evidence‐based practice where available and established best practice where evidence is unavailable. It is not possible to consider all the potential decisions in managing MG without resorting to opinion rather than evidence. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians in using the right treatments in the right order and in optimizing the use of well‐known therapeutic agents. Clinical practice can be audited against these guidelines.